Investing in proven biosimilars in ophthalmology and oncology
Valorum is interested in assets with clear and defined paths to approval and high returns on investment. Our pipeline aims to provide cost-effective and timely solutions to patients’ unmet needs.
Pipeline
preclinical
phase iphase iiiFDA/EMA Approval
VA-1*
Ophthalmology
VA-2
Oncology
| Indications | Phase/Status | |
|---|---|---|
|
VA-1* Ophthalmology |
|
FDA/EMA Approval |
| VA-2 Oncology |
Phase III |
* EMA Approved